Nuplazid Safety Review: Blast From the Past Or Preview Of Future Terrors?

Fueled by Congress, media attention, reevaluation of Acadia's Parkinson's drug feels like a scandal from pharma's primary care era – but is also a glimpse of what things might look like for industry if Democrats retake the House.